Global Argatroban Market Overview:
Argatroban is a crystalline powder that is odorless and freely soluble in glacial acetic acid. Argatroban, an anticoagulant, is a direct thrombin inhibitor that has been licensed by the FDA for prophylaxis or thrombosis in patients with heparin-induced thrombocytopenia (HIT). Adult patients with or at risk of HIT who are undergoing percutaneous coronary intervention should get Argatroban Injection (PCI). Heparin is a more regularly used thrombin inhibitor, although it can cause a platelet count shortage in some people. This has increased the demand for a heparin substitute. Argatroban meets this need by working as a thrombin inhibitor that does not cause heparin-like side effects. Because of the rising incidence of heparin-related problems and the growth in the number of cerebral arterial thrombosis, the argatroban market is expected to develop throughout the near future.
- Increase in the Number of Heparin-Related Complications
- Rise in Incidence of Percutaneous Coronary Intervention Procedures
- Rising Allergies Associated with Argatroban
- Growing Research and Development Activities
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer, Inc (United States), Caplin Point Laboratories Ltd (India), Novartis (Switzerland), GlaxoSmithKline Plc (United Kingdom), Fresenius-Kabi (Germany), Eagle Pharmaceuticals, Inc (United States), Mitsubishi Tanabe Pharma (Japan), Teva Pharmaceutical Industries Ltd (Israel), WEST-WARD,INC (United States), Midas Pharma GmBH (Germany) and Aurobindo Pharma Limited (India). Analyst at AMA Research see European Players to retain maximum share of Global Argatroban market by 2026. Considering Market by End-Use, the sub-segment i.e. Hospitals will boost the Argatroban market.
January 2020 – Caplin Point Laboratories announced that its subsidiary, Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Argatroban Injection, 50 mg/50 ml (1 mg/ml) Single-dose vial presentation, a generic therapeutic equivalent version of (RLD), ARGATROBAN INJECTION, of Hikma Pharmaceuticals.
What Can be Explored with the Argatroban Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Argatroban Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Argatroban
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Argatroban market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Argatroban market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Argatroban, Suppliers of Argatroban, Hospitals, Pharmaceutical Companies, Investors and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Argatroban Market?
The Argatroban market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Argatroban Market?
Top performing companies in the Global Argatroban market are Pfizer, Inc (United States), Caplin Point Laboratories Ltd (India), Novartis (Switzerland), GlaxoSmithKline Plc (United Kingdom), Fresenius-Kabi (Germany), Eagle Pharmaceuticals, Inc (United States), Mitsubishi Tanabe Pharma (Japan), Teva Pharmaceutical Industries Ltd (Israel), WEST-WARD,INC (United States), Midas Pharma GmBH (Germany) and Aurobindo Pharma Limited (India), to name a few.
3. What trending factors would impact Argatroban Market growth most?
"Rising Incidence of Cerebral Arterial Thrombosis" is seen as one of major influencing trends for Argatroban Market during projected period 2020-2026.